Free tool
FAERS Monitor: Taytulla
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204426 or its brand name (Taytulla, Ethinyl Estradiol, Norethindrone Acetate). Reports on generic versions are filed under their own applications.
Reports
318
Serious
73
23% of reports
Hospitalization
25
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use45
- drug ineffective34
- recalled product administered34
- nausea20
- pregnancy20
- headache16
- metrorrhagia16
- product dose omission13
- pruritus13
- anxiety11
- dizziness9
- pregnancy on oral contraceptive9
- product use issue9
- recalled product9
- vomiting9
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 4 |
| 2016 | 5 |
| 2017 | 17 |
| 2018 | 93 |
| 2019 | 96 |
| 2020 | 48 |
| 2021 | 27 |
| 2022 | 9 |
| 2023 | 8 |
| 2024 | 5 |
| 2025 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,841 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| recalled productSignal | 9 | 345.8 | 181.3 | 2,745 |
| recalled product administeredSignal | 34 | 236.6 | 172.1 | 7,720 |
| pregnancy on oral contraceptiveSignal | 9 | 227.9 | 119.5 | 1,806 |
| pregnancySignal | 20 | 66.1 | 43.3 | 1,219 |
| metrorrhagiaSignal | 16 | 62.1 | 38.5 | 902 |
| product dose omissionSignal | 13 | 13.2 | 7.7 | 135 |
| off label useSignal | 45 | 3.4 | 2.6 | 77 |
| product use issueSignal | 9 | 3.2 | 1.7 | 11 |
| anxietySignal | 11 | 2.6 | 1.4 | 9 |
| pruritusSignal | 13 | 2.2 | 1.3 | 8 |
| drug ineffective | 34 | 1.7 | 1.2 | 10 |
| headache | 16 | 1.7 | 1.0 | 4 |
| nausea | 20 | 1.7 | 1.1 | 5 |
| vomiting | 9 | 1.3 | 0.7 | 0 |
| dizziness | 9 | 1.2 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.